Treatment Nonexistent for Some Glioblastoma Patients
Study shows treatment more likely and improved survival at high-volume centers
Patients diagnosed at high-volume centers are up to 40 percent more likely to receive treatment for glioblastoma, according to a study from researchers at the University of Illinois at Chicago.
The study, which is one of the largest on glioblastoma treatment and outcomes, also shows that patients treated at high-volume centers live approximately three and one-half months longer than patients treated at low-volume centers.
Dr. Matthew Koshy, corresponding author on the paper, says this difference in outcomes is on par with results seen in phase III clinical trials—the last of which for glioblastoma was two years ago.
Click here to read more.
NeuroSafe 2019 Symposium
Aug. 8-9, 2019; Minneapolis
SNSA Congress 2019
Aug. 8-11, 2019; Cape Town, South Africa
2019 Managing Coding and Reimbursement Challenges
Aug. 22-24, 2019; Rosemont, Ill.
2019 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 28-31, 2019; Orlando, Fla.
Sept. 8-11, 2019; Leuven, Belgium